BOT Welcomes First FDA Approval for Cannabidiol Product
Filed with ASX · · 3 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Botanix Raises A$8m in Oversubscribed Placement
- Australian Ethics approval for Acne Study
- BTX 1204 Atopic Dermatitis Study Results Presentation
- Botanix Announces Successful Atopic Dermatitis Study Results
- Presentation on Atopic Dermatitis Market
Later from Botanix Pharmaceuticals
- First Patients Recruited into BTX 1503 Phase 2 Acne Trial
- Botanix update on development pipeline products
- Botanix Joins with UQ to Accelerate Development of BTX 1801
- Investigators Meeting Completed for BTX 1503 Phase 2 Trial
- FDA Clears Development Path for BTX 1204
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals